Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.40 |
| ▸ | CA2 | P00918 | 9/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | CA5A | P35218 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elsulfavirine SCHEMBL1341521 | 1.00 | CA1 (0.40) | CA1CA2CA12CA9CYP3A4 | |
| Elsulfavirine SCHEMBL1344214 | 0.99 | CA1 (0.39) | CA1CA2CA12CA9CYP3A4 | |
| SCHEMBL24371887 | 0.93 | CA1 (0.40) | CA1CA2CA12CA9CYP3A4 | |
| SCHEMBL2638424 | 0.93 | CYP3A4 (0.43) | CA1CA2CA12CA9CYP3A4 | |
| SCHEMBL2638432 | 0.92 | CYP3A4 (0.46) | CA1CA2CA12CA9CYP3A4 | |
| SCHEMBL12132127 | 0.89 | CA1 (0.44) | CA1CA2CA12CA9THRA | |
| Depulfavirine SCHEMBL2638090 | 0.89 | CA1 (0.52) | CA1CA2CA12CA9CA5A | |
| Depulfavirine SCHEMBL29421868 | 0.89 | CA1 (0.52) | CA1CA2CA12CA9CA5A | |
| SCHEMBL3937009 | 0.88 | SLC22A12 (0.39) | CA1CA2CA12THRATHRB | |
| SCHEMBL2639193 | 0.88 | CYP3A4 (0.42) | CA1CA2CA12CA9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2023082131-A | Polymorphs of acyl sulfonamides | エフ. ホフマン-ラ ロシュ アーゲー | 2023-06-13 | — | — | JP | disclosed |
| EP-2334638-B1 | POLYMORPHS OF ACYL SULFONAMIDES | HOFFMANN LA ROCHE (CH) | 2018-11-21 | — | — | EP | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-8063103-B2 | Polymorphs of acyl sulfonamides | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2334638-A2 | POLYMORPHS OF ACYL SULFONAMIDES | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010028968-A2 | POLYMORPHS OF ACYL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063154-A1 | POLYMORPHS OF ACYL SULFONAMIDES | ROCHE PALO ALTO LLC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063154-A1 | POLYMORPHS OF ACYL SULFONAMIDES | ARSA, AADAC, SULT2A1 | CA1 4005/4885CA2 1587/4885CA12 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.